Le Lézard
Classified in: Health, Science and technology, Business
Subject: CXP

Shield Diagnostics Receives College of American Pathology (CAP) Accreditation

SAN JOSE, Calif., Aug. 14, 2019 /PRNewswire/ -- Shield Diagnostics, an Andreessen Horowitz-backed biotechnology company tackling antibiotic resistance by bringing precision medicine to infectious disease, announced today that it has been awarded accreditation by the College of American Pathologists (CAP).

Shield Diagnostics Logo

"Receiving CAP accreditation is an important recognition of our laboratory. It means that our test results are meeting and exceeding industry standards for clinical laboratory testing," said Arthur Baca, M.D. Ph.D., Laboratory Director.

Shield Diagnostics' Chief Executive Officer, Fred Turner, upon learning of the laboratory's accreditation, said: "We are proud of our diligent and experienced clinical lab team. Their meticulous work ensures that we maintain the highest standards of excellence in laboratory practices. By providing accurate and rapid test results for the susceptibility of pathogens to less potent antibiotics, we hope to end the abuse of our last defense antibiotics."

During the CAP accreditation process, inspectors perform an on-site inspection and examine the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.

About the College of American Pathologists

As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP Annual Report at cap.org.

About Shield Diagnostics

Shield Diagnostics is a biotechnology company with a vision of preventing antibiotic resistance from growing deadlier than cancer.  With a mission to enable resistance-guided therapy, Shield Diagnostics is developing rapid molecular testing to target antibiotic use to the specific infection. Our first rapid molecular test, Target-NG, evaluates gonorrhea infections for antibiotic susceptibility to ciprofloxacin, as a reflex to gonorrhea, chlamydia, and trichomoniasis testing in our CLIA & CAP accredited laboratory in San Jose, CA. Currently, Shield Diagnostics is the only laboratory in the industry that offers a gonorrhea reflex test for antibiotic susceptibility to ciprofloxacin. For more information, visit https://shielddx.com/.


SOURCE Shield Diagnostics

These press releases may also interest you

at 02:05
Agilent Technologies Inc. announced today that Professor Hualiang Jiang has received an Agilent Thought Leader Award. Professor Jiang directs the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences and is a leading researcher in...

at 01:05
Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with BioLizard, an innovative bioinformatics company that...

at 01:05
Takeda Pharmaceutical Company Limited ("Takeda") (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score. In addition, Takeda was...

at 00:05
Last year, over 23,500 youth (age 10 to 24) were hospitalizedi for harm caused by substance use ? the equivalent of 65 hospitalizations each day. A new report from the Canadian Institute for Health Information (CIHI) shows that cannabis and alcohol...

at 00:01
An article recently published in Radiology highlights the groundbreaking use of a new imaging technology introduced by Seno Medical Instruments, Inc.® (Seno Medical) to diagnose breast cancer. The technology may offer physicians a new, non-invasive...

at 00:00
Attorney Corsello has been practicing personal injury litigation and criminal law for over 35 years. He received his JD degree from Suffolk University Law School and his BA degree from the University of Connecticut. He was admitted to the Connecticut...

News published on 14 august 2019 at 09:11 and distributed by: